Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?
Henry Schein (HSIC) posted solid third-quarter 2023 sales growth and non-GAAP EPS growth despite continued lower sales of PPE products and COVID-19 test kits. In addition, the company’s long-term outlook appears bright, driven by sustained demand for its healthcare solutions and strategic investments. So, is it worth adding this medical…
StockNews.com ·